<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hidradenitis suppurativa: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hidradenitis suppurativa: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hidradenitis suppurativa: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Ingram, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Owen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hidradenitis suppurativa (HS) is a chronic, painful, follicular, occlusive disease that affects the folliculopilosebaceous unit mainly, but not exclusively, in intertriginous axillary, groin, perianal, perineal, genital, and inframammary skin. The clinical course is highly variable, ranging from relatively mild disease characterized by the recurrent appearance of papules, pustules, and a few inflammatory nodules to severe cases demonstrating deep, fluctuant abscesses; draining skin tunnels; and severe, rope-like scars  (<a class="graphic graphic_picture graphicRef90465" href="/z/d/graphic/90465.html" rel="external">picture 1A</a>).</p><p>Numerous interventions exist for the treatment of HS, including topical therapies, oral therapies, biologic therapies, surgery, and laser and light interventions. Disease severity, patient tolerance of specific agents, comorbidities, and treatment cost and availability guide treatment selection  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>).</p><p>The management of HS will be reviewed here. Information on the pathogenesis, clinical features, and diagnosis of HS and a detailed discussion of the surgical techniques used in the treatment of HS are provided separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa"</a>.)</p><p></p><p class="headingAnchor" id="H856174"><span class="h1">GOALS OF TREATMENT</span><span class="headingEndMark"> — </span>HS is a chronic condition, and the pain, drainage, odor, and disfigurement caused by HS profoundly affect quality of life, even when the disease is relatively mild [<a href="#rid1">1-3</a>]. Feelings of shame may produce self-imposed social isolation and, combined with chronic pain, likely contribute to higher rates of depression and anxiety [<a href="#rid4">4-7</a>]. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Interventions for HS target one or more of three major goals:</p><p class="bulletIndent1"><span class="glyph">●</span>To reduce formation of new inflammatory lesions, skin tunnels, and scarring</p><p class="bulletIndent1"><span class="glyph">●</span>To treat existing lesions and reduce associated symptoms (eg, pain, suppuration)</p><p class="bulletIndent1"><span class="glyph">●</span>To minimize impact on quality of life and associated psychologic morbidity</p><p></p><p class="headingAnchor" id="H16990907"><span class="h1">ASSESSMENT OF DISEASE SEVERITY AND RESPONSE</span><span class="headingEndMark"> — </span>The severity of HS influences the approach to treatment. Key features used to determine disease severity include the extent of skin involvement and the presence of secondary lesions, including skin tunnels and scarring. Responses to treatment are indicated by reduced frequency and severity of inflammatory lesions, improvement in symptoms, and improvement in quality of life.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical setting</strong> – In addition to describing the features present, common methods of defining disease severity in the clinical setting include the three-stage Hurley clinical staging system and use of the terms "mild," "moderate," and "severe" [<a href="#rid8">8</a>]. Hurley stage I HS is generally considered to correlate with mild disease, and stages II and III may be considered to represent the continuum of moderate to severe disease.</p><p></p><p class="bulletIndent1">The Hurley staging system stratifies HS severity as follows [<a href="#rid8">8</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage I </strong>– Abscess formation (single or multiple) without skin tunnels and cicatrization/scarring  (<a class="graphic graphic_picture graphicRef90463" href="/z/d/graphic/90463.html" rel="external">picture 2</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage II </strong>– Recurrent abscesses with skin tunnels and scarring, single or multiple widely separated lesions  (<a class="graphic graphic_picture graphicRef90464" href="/z/d/graphic/90464.html" rel="external">picture 1C</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage III </strong>– Diffuse or almost diffuse involvement, or multiple interconnected skin tunnels and abscesses across the entire area  (<a class="graphic graphic_picture graphicRef90465 graphicRef65188" href="/z/d/graphic/90465.html" rel="external">picture 1A-B</a>)</p><p></p><p class="bulletIndent1">The term "abscess" is typically considered to include both inflammatory nodules and true abscesses when staging HS.</p><p></p><p class="bulletIndent1">Assessment of the impact of treatment both on skin disease and patient quality of life is useful for determining treatment benefit. In addition to the clinician's physical examination at follow-up visits, patients can be asked to record the number of new or recurrent, painful lesions occurring in the preceding month. Asking patients to complete a quality-of-life instrument, such as the Dermatology Life Quality Index, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score [<a href="#rid9">9</a>], or a pain visual analog or numeric scale, may also be helpful  (<a class="graphic graphic_form graphicRef82442" href="/z/d/graphic/82442.html" rel="external">form 1</a> and <a class="graphic graphic_figure graphicRef72905" href="/z/d/graphic/72905.html" rel="external">figure 1</a>)<strong> </strong>[<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical trials</strong> – The Hurley staging system is often used in the clinical setting due to its simplicity. However, it has insufficient responsiveness to change to be used as a clinical trial outcome measure. Newer assessment tools, such as the Hidradenitis Suppurativa Clinical Response (HiSCR) and International Hidradenitis Suppurativa Severity Score System (IHS4), have been developed and validated [<a href="#rid12">12-14</a>]. In addition, the <strong>Hi</strong>dradenitis <strong>S</strong>uppura<strong>t</strong>iva C<strong>or</strong>e outcomes set <strong>I</strong>nternational <strong>C</strong>ollaboration (HISTORIC) has identified six core domains to measure in all future HS trials: pain, physical signs, HS-specific quality of life, global assessment, progression of course, and symptoms (drainage and fatigue) [<a href="#rid15">15,16</a>].</p><p></p><p class="headingAnchor" id="H41871344"><span class="h1">INTERVENTIONS FOR ALL PATIENTS</span><span class="headingEndMark"> — </span>The multifaceted clinical features of HS and the unpredictable course of the disease make a uniform approach to treatment challenging. Regardless of disease severity, attention to patient education; patient support; and appropriate management of wounds, pain, and comorbidities can be beneficial [<a href="#rid17">17,18</a>]. (See <a class="local">'Education and support'</a> below and <a class="local">'Wound and skin care'</a> below and <a class="local">'Pain management'</a> below and <a class="local">'Assessment and management of comorbidities'</a> below.)</p><p class="headingAnchor" id="H3378650836"><span class="h2">Education and support</span><span class="headingEndMark"> — </span>HS is a psychologically distressing disorder that can have a major impact on quality of life and is often associated with several years or more of diagnostic delay, making patient education and support essential components of management [<a href="#rid19">19</a>]. We suggest the following interventions:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be educated about the diagnosis of HS. We typically communicate the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HS is a chronic, inflammatory condition that is neither contagious nor due to poor hygiene.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although HS has been associated with smoking and obesity, HS can also occur in the absence of these characteristics. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A family history of HS is common among individuals with HS. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The course of HS varies from person to person; reliable predictors of progression to more severe disease have not been identified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinician should inquire about the impact of the disease on the patient's life and assess the patient's specific concerns and needs regarding the condition [<a href="#rid20">20</a>]. An assessment for signs or symptoms of depression should be included [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">"Screening for depression in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be offered resources for psychologic support [<a href="#rid5">5</a>], such as contact information for local HS patient societies. Patients may find the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hs-foundation.org%2F&amp;token=u%2FUXY8mj4f2cUyB56IXs7tqdobTj8l%2FgdcPx85TbAdkcCU%2BZ8XRBfAX5nR7umXm6&amp;TOPIC_ID=7605" target="_blank">Hidradenitis Suppurativa Foundation</a> and other resources helpful.</p><p></p><p class="headingAnchor" id="H3839171143"><span class="h2">Wound and skin care</span><span class="headingEndMark"> — </span>Providing patients with guidance regarding care techniques for draining lesions and wounds can be helpful. In general, patients should utilize wound dressings that minimize skin trauma. To prevent absorbent dressings from sticking to the wound, simple white petrolatum can be applied. Adhesive tape should be avoided, and instead, elastic fishnet dressings can be customized to hold absorbent material in place.</p><p>Topical antiseptic washes, such as <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> 4%, <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a>, or <a class="drug drug_general" data-topicid="10237" href="/z/d/drug information/10237.html" rel="external">zinc pyrithione</a>, to cleanse skin in the affected areas might be beneficial [<a href="#rid22">22</a>]. However, evidence to confirm benefit of these interventions for improving HS is lacking, and advising use of these products may contribute to patient stigma in terms of a link to poor skin hygiene. We do not prescribe these agents routinely but have some patients who report that their use of topical antiseptic agents has seemed beneficial.</p><p class="headingAnchor" id="H3477927988"><span class="h2">Pain management</span><span class="headingEndMark"> — </span>Pain from HS nodules and abscesses may cause sleep disturbance, limit function, and induce psychologic distress. Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used to treat both pain and inflammation. Additional analgesia, including opioid analgesia, may be needed in some cases [<a href="#rid23">23</a>].</p><p>Conscientious selection of pain medication, particularly opioids, is indicated. A multidisciplinary approach may be helpful for identifying an appropriate pain management plan for patients experiencing chronic pain. The approach to the management of chronic pain is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H2790690311"><span class="h2">Assessment and management of comorbidities</span><span class="headingEndMark"> — </span>Patients with HS may be at increased risk for multiple health disorders, including alcohol dependence, autoimmune conditions, cardiovascular disease, diabetes, drug dependence, dyslipidemia, follicular occlusion syndromes (including pilonidal sinus), hypertension, inflammatory arthropathies, cutaneous squamous cell carcinoma, metabolic syndrome, nicotine addiction, obesity, polycystic ovary syndrome (PCOS), and psychiatric and psychologic disorders  (<a class="graphic graphic_table graphicRef75490" href="/z/d/graphic/75490.html" rel="external">table 1</a>) [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H3207047002"><span class="h3">Patient evaluation</span><span class="headingEndMark"> — </span>We agree with recommendations from the United States and Canadian Hidradenitis Suppurativa Foundations and guidelines from the British Association of Dermatologists that support routine screening of patients with HS for comorbidities [<a href="#rid17">17,26</a>]. Our approach, which is loosely based upon these sources, is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Perform a review of systems and physical examination to screen for acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, tobacco use, obesity, hypertension, PCOS, inflammatory bowel disease, autoinflammatory syndromes, inflammatory arthropathy, and sexual dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain laboratory testing to screen for diabetes mellitus, hyperlipidemia, and anemia [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">"Screening for type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screen for depression, anxiety, substance use disorders, and suicidality using a recognized screening tool for these conditions. (See  <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">"Screening for depression in adults"</a> and  <a class="medical medical_review" href="/z/d/html/496.html" rel="external">"Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis", section on 'Screening, assessment, and diagnosis'</a>.)</p><p></p><p>Recommendations from a multispecialty working group for the management of comorbidities, including cardiovascular risk factors, excess weight, inflammatory bowel disease, inflammatory joint disorders, psychologic disorders, alcohol use, and tobacco use, in patients with HS have also been published [<a href="#rid28">28</a>]. The document provides guidance for dermatologists for patient assessment and referral and reviews the implications of treatments for HS on comorbidities. We agree with the importance of assessing for comorbidities on a yearly basis and support multidisciplinary involvement in the management of comorbidities.</p><p class="headingAnchor" id="H41102989"><span class="h3">Smoking cessation and weight loss</span><span class="headingEndMark"> — </span>Smoking and obesity are common among patients with HS. Pathogenic roles for these environmental factors in the development and persistence of HS have been proposed but not definitively proven [<a href="#rid29">29-33</a>]. In the case of obesity, conditions related to excess weight, such as skin occlusion, skin friction, shearing forces on skin, hyperinsulinemia, and other hormonal changes that occur in association with obesity, are proposed to contribute. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated factors'</a>.)</p><p>Although benefits of smoking cessation and weight loss on HS severity are postulated, data conflict and benefit of these interventions has not been confirmed. We routinely advise smoking cessation or weight loss to our patients with HS who smoke or are obese based upon the potential for benefit in HS, the other recognized health benefits of these interventions, and observations that support increased risk for morbidity or mortality from related conditions among patients with HS, such as cardiovascular diseases [<a href="#rid34">34</a>]. <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a>, one of the medications used to treat HS, may have a modest beneficial effect on weight loss. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated factors'</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a> and <a class="local">'Metformin'</a> below.)</p><p>Additional study to clarify whether smoking cessation and weight loss improve HS is warranted. A retrospective survey of 45 Danish patients who underwent bariatric surgery suggests benefit; of the 35 patients who achieved substantial weight loss, defined as at least a 15 percent reduction in baseline body mass index, 17 (49 percent) experienced resolution of their HS, 7 (20 percent) improved, 7 (20 percent) had unchanged disease, and 4 (11 percent) had worsened disease [<a href="#rid35">35</a>]. In addition, improvement in HS after smoking cessation has been documented in case reports [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2131349963"><span class="h1">INFLAMMATORY LESIONS WITHOUT SKIN TUNNELS OR SCARRING (HURLEY STAGE I OR MILD DISEASE)</span><span class="headingEndMark"> — </span>The initial management of patients in whom HS manifests as inflammatory lesions without skin tunnels or scarring (Hurley stage I or mild HS) consists of therapies to reduce disease burden (ie, reduce lesion development and inhibit disease progression) and interventions to improve acute, symptomatic lesions  (<a class="graphic graphic_picture graphicRef90463" href="/z/d/graphic/90463.html" rel="external">picture 2</a>). (See <a class="local">'Reducing burden of disease'</a> below and <a class="local">'Acute, symptomatic lesions'</a> below.)</p><p class="headingAnchor" id="H1749236509"><span class="h2">Reducing burden of disease</span><span class="headingEndMark"> — </span>Common therapies for reducing disease burden in mild HS include oral tetracyclines, oral antiandrogenic agents, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, and topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>.</p><p class="headingAnchor" id="H498473989"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Oral tetracyclines are our usual initial treatments for HS presenting as inflammatory lesions without skin tunnels or scarring  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). Oral antiandrogenic drugs and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> are additional treatment options that may be used alone or in conjunction with antibiotics.</p><p>Consideration of patient characteristics, patient preference, and drug adverse effects influence the decision to incorporate an oral antiandrogenic drug or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. For patients initially treated with antibiotics, these drugs may be added early in the course of antibiotic treatment or after antibiotic therapy proves insufficient  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). We tend to add antiandrogenic drugs earlier for female patients who report flares of HS in association with menses or who have features of polycystic ovary syndrome [<a href="#rid22">22</a>]. Additional effects of metformin that may prompt early use of the drug in patients with HS and obesity (a potential exacerbating factor for HS) include modest weight loss and beneficial effects on metabolic profile. (See <a class="local">'Oral tetracyclines'</a> below and <a class="local">'Antiandrogenic agents'</a> below and <a class="local">'Metformin'</a> below and  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated factors'</a>.)</p><p>Topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> is sometimes tried prior to proceeding to oral agents and may be a reasonable alternative initial approach for patients with mild disease. However, our experience suggests that topical clindamycin monotherapy is rarely sufficient for controlling HS. Our use of topical clindamycin is primarily limited to use as an adjunctive therapy. (See <a class="local">'Topical clindamycin'</a> below.)</p><p class="headingAnchor" id="H3140448908"><span class="h4">Oral tetracyclines</span><span class="headingEndMark"> — </span>The mechanism by which antibiotic therapy improves HS is not definitively known. Antibiotics may help to control skin bacterial load, which may be an exacerbating factor for HS. However, the anti-inflammatory effects associated with some antibiotics may also play a role [<a href="#rid37">37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – A common regimen for adults is 100 mg of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> given once to twice daily. Examples of alternative <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> regimens include lymecycline (at a dose of 408 mg once or twice daily) and tetracycline (at a dose of 500 mg twice daily). <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> (at a dose of 100 mg twice daily) is an additional option but has the disadvantage of a broader side effect profile. Lymecycline is not available in the United States.</p><p></p><p class="bulletIndent1">Data are insufficient to confirm the best approach to <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> therapy. Tetracyclines are typically given for a few months, though longer treatment courses are often used [<a href="#rid22">22,38</a>]. We typically assess the response to tetracyclines after three months  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). If the response is satisfactory, we stop the antibiotic and follow the patient for recurrence of disease activity. If there is progressive but insufficient improvement, we often continue the antibiotic for an additional two to three months prior to reassessing the efficacy of therapy. If the response is minimal to absent, we stop the antibiotic and proceed to other therapies. (See <a class="local">'Refractory disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Randomized trial evidence for oral tetracyclines is sparse. In a trial, 46 patients with stage I or II HS were randomly assigned to treatment with oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (at a dose of 500 mg twice daily) or topical 1% <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> solution (applied twice daily) [<a href="#rid39">39</a>]. Patients were treated for 16 weeks, and while there was no difference between the groups in terms of pain, number of lesions, or physician global assessment, there was a greater improvement in patient global assessment of disease in the oral tetracycline group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Treatment with tetracyclines is generally well tolerated. Common adverse effects include gastrointestinal distress and photosensitivity. <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> may also cause vertigo, skin discoloration, and a lupus-like syndrome.</p><p></p><p class="headingAnchor" id="H3918266371"><span class="h4">Antiandrogenic agents</span><span class="headingEndMark"> — </span>Antiandrogenic therapy for HS is based upon the theory that androgens may contribute to the development of HS [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated factors'</a>.)</p><p>Examples of antiandrogenic therapies that may improve the disease include combined oral contraceptives, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, and <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> [<a href="#rid40">40-46</a>]. High-quality efficacy data for these therapies are limited, and relative efficacy is unclear [<a href="#rid17">17</a>]. Antiandrogenic therapy should <strong>not</strong> be given to pregnant patients because of the risk for adverse effects on the fetus.</p><p>Selection of an antiandrogenic agent is based upon consideration of patient preference, contraceptive needs, and comorbidities. We typically treat female patients with oral contraceptives or <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>; efficacy data for <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> are more limited.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral contraceptives</strong> – Use is limited to female patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – Oral contraceptives are taken daily, identical to the regimen advised for contraception. The response may be assessed after three to six months of treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – An oral contraceptive regimen containing <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> and ethinyl estradiol was compared with norgestrel-containing oral contraceptive pills in a randomized, double-blind, crossover trial of 24 females with moderate to severe HS [<a href="#rid40">40</a>]. Patients were treated with 50 mcg of ethinyl estradiol (cycle days 5 to 25) and 50 mg of cyproterone acetate (cycle days 5 to 14) for six months and <a class="drug drug_general" data-topicid="9437" href="/z/d/drug information/9437.html" rel="external">ethinyl estradiol-norgestrel</a> 50 mcg/500 mcg (cycle days 5 to 25) for six months. Although six patients dropped out of the trial prior to completion due to drug intolerance or worsening of disease, both treatment regimens were associated with clinical improvement in disease activity, and no significant difference in efficacy was detected. Overall, improvement occurred in 12 patients, including 7 patients who achieved complete remissions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Precautions</strong> – Oral contraceptive therapy is usually well tolerated but is associated with a variety of risks and adverse effects. Clinicians should assess for contraindications to oral contraceptive drugs prior to initiating therapy. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spironolactone</strong> – Use is limited to female patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – A typical dose of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> is 100 mg per day, though doses utilized range from 25 to 200 mg per day. Starting at a lower dose (eg, 50 mg per day) and subsequently increasing to 100 mg per day after a few weeks may help to optimize patient tolerance of the drug. Responses to spironolactone are usually evident within three months. The response may be assessed after three to six months of treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – Retrospective studies of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> for HS suggest benefit [<a href="#rid42">42,46,47</a>]. A retrospective study of 67 female patients with Hurley stage I to III HS (74 percent with Hurley stage II HS) associated spironolactone therapy with improvement in pain, inflammatory lesion count, and physician-assessed disease severity [<a href="#rid46">46</a>]. Patients received 25 to 200 mg of spironolactone per day (average dose 75 mg per day) and were followed for an average of 7 months (range 0.75 to 28 months). Treatment with spironolactone was well tolerated; only two patients discontinued the drug because of side effects. Some patients also received antibiotics, hormonal contraceptives, or other HS therapies.</p><p></p><p class="bulletIndent2">In addition, a retrospective case series of 20 female patients given <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, most at a dose of 100 mg daily, reported remission in 11 patients (55 percent) and clinical response in 17 patients (85 percent) after three months [<a href="#rid42">42</a>]. Five patients were given concomitant <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> 100 mg daily, and seven patients received an oral contraceptive pill.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Precautions</strong> – Potential side effects of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> include menstrual irregularities, breast tenderness, hypotension, central nervous system symptoms (headaches, dizziness, fatigue), and hyperkalemia. Although an increase in mammary tumors has been reported in rats treated with spironolactone, a relationship between spironolactone and human cancers has not been proven. (See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Spironolactone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Finasteride</strong> – Small case series have suggested benefit from <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> in female and male patients [<a href="#rid43">43,44,48</a>]. Doses of finasteride for HS range from 1.25 to 5 mg per day. Finasteride is contraindicated in individuals of childbearing potential. We do not typically utilize finasteride for HS.</p><p></p><p class="headingAnchor" id="H2724086376"><span class="h4">Metformin</span><span class="headingEndMark"> — </span>Insulin and insulin-like growth factor may contribute to HS, providing a potential mechanism for benefit of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. In addition, metformin exerts an antiandrogenic effect and can promote modest weight loss, which may also be beneficial for HS. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Associated disorders and syndromes'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> is given daily with food. An initial dose of 500 mg is often prescribed and titrated upward by 500 mg every few weeks as tolerated. Our typical maximum dose is 1500 mg per day given in two or three divided doses (eg, 500 mg three times per day). Extended-release metformin may allow for less frequent dosing. Metformin is contraindicated in patients with severe renal dysfunction. Responses to treatment may be evident within the first three months [<a href="#rid49">49</a>]. The response to metformin may be assessed after three to six months of treatment. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Suggested approach to the use of metformin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Support for the efficacy of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> for HS stems from uncontrolled studies [<a href="#rid49">49,50</a>]. In a 24-week, prospective study of 25 nondiabetic patients with HS who were treated with metformin (initial dose 500 mg per day, maximum dose 500 mg three times per day), almost all of whom had failed to achieve sufficient responses to other therapies [<a href="#rid49">49</a>], 18 patients achieved clinical improvement, including 7 who achieved at least a 50 percent reduction in the Sartorius score. In addition, in a retrospective case series of 53 patients treated with metformin as monotherapy (mean daily dose 1500 mg per day) for at least one month, the examining dermatologist recorded subjective improvement in 36 patients (68 percent), including complete response (no active lesions) in 7 patients (19 percent) demonstrating improvement [<a href="#rid50">50</a>]. The mean duration of treatment was 11 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Gastrointestinal adverse effects are the most common side effects of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> therapy and can limit use of the drug in some patients. Adverse effects of metformin, including increased risk for vitamin B12 and folate deficiency, are reviewed in greater detail separately. (See  <a class="drug drug_general" href="/z/d/drug information/9621.html" rel="external">"Metformin: Drug information"</a> and  <a class="medical medical_review" href="/z/d/html/7153.html" rel="external">"Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Metformin'</a>.)</p><p></p><p class="headingAnchor" id="H2174299765"><span class="h4">Topical clindamycin</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> may improve HS through reducing inflammatory lesions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The drug is typically applied two times per day in skin areas subject to recurrent flares. The response may be assessed after three months of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and precautions</strong> – Although frequently prescribed, data to support efficacy of topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> are limited. In a three-month trial in which 30 patients with HS of the axillae and/or groin were randomly assigned to treatment with either clindamycin 1% solution or vehicle, an analysis of the effect on an unvalidated cumulative disease burden score for the 13 patients in the clindamycin group and 14 patients in the vehicle group that completed treatment demonstrated greater improvement in the clindamycin group than in the vehicle group after one, two, and three months of treatment [<a href="#rid51">51</a>]. Topical clindamycin was well tolerated; slight burning pain after application occurred in two patients in the clindamycin group and three in the vehicle group.</p><p></p><p class="headingAnchor" id="H2481487598"><span class="h3">Refractory disease</span><span class="headingEndMark"> — </span>Patients with mild HS that fails to improve with the treatments above may benefit from some of the therapies used for more severe disease.</p><p>In general, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> combination therapy, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> are viewed as appropriate systemic options for mild HS resistant to initial therapies  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>) [<a href="#rid22">22</a>]. Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy has also been used in this setting. (See <a class="local">'Nd:YAG laser'</a> below.)</p><p>Treatment with biologic agents, intravenous antibiotics, and immunosuppressive therapies are generally reserved for patients presenting with greater disease severity. (See <a class="local">'Inflammatory lesions with skin tunnels or scarring (Hurley stage II or III, moderate to severe disease)'</a> below.)</p><p class="headingAnchor" id="H3855438223"><span class="h4">Clindamycin and rifampin, acitretin, or dapsone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> therapy and combination therapy with <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> are reviewed below. (See <a class="local">'Acitretin'</a> below and <a class="local">'Clindamycin and rifampin'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapsone</strong> – <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a>, a sulfone drug with immunomodulatory and antibacterial properties that is utilized for the treatment of multiple neutrophil-predominant skin diseases, may be effective in mild to moderate HS, particularly in the early, neutrophil-mediated phase of new lesions [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – We typically treat adults with 50 mg per day and increase to 100 mg per day if insufficient response. Responses may be evident within the first one to three months of treatment [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – In a retrospective study of 24 patients with Hurley stage I to III HS who were treated with 50 to 200 mg daily of <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, six patients (25 percent) achieved clinically significant improvement, and three patients (13 percent) improved slightly [<a href="#rid52">52</a>]. None of the four patients with stage III disease improved with therapy. In addition, dapsone (at a dose of 25 to 150 mg per day) was associated with reductions in disease severity in a case series of five patients [<a href="#rid53">53</a>]. As with other medical agents, the disease often recurs after treatment cessation [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Precautions</strong> – Hemolysis is a common and expected adverse effect of <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> therapy, and careful laboratory monitoring for hematologic toxicity is necessary during treatment. It is prudent to test for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to treatment to avoid severe hemolysis in the G6PD-deficient population. Examples of additional adverse effects of dapsone include methemoglobinemia (which manifests with headaches), agranulocytosis, and a hypersensitivity reaction [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p></p><p class="headingAnchor" id="H3343725572"><span class="h2">Acute, symptomatic lesions</span><span class="headingEndMark"> — </span>Intermittent application of warm compresses is a simple measure that may help to improve symptomatic lesions. Additional interventions for symptomatic, inflamed nodules include intralesional corticosteroid injections, punch debridement (partial unroofing), and topical resorcinol  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). The efficacy of these interventions has not been compared; treatment selection is often based upon treatment availability and patient preference. (See <a class="local">'Intralesional corticosteroids'</a> below and <a class="local">'Punch debridement'</a> below and <a class="local">'Topical resorcinol'</a> below.)</p><p>Routine incision and drainage of HS lesions is <strong>not</strong> recommended. (See <a class="local">'Incision and drainage'</a> below.)</p><p class="headingAnchor" id="H1460227017"><span class="h3">Intralesional corticosteroids</span><span class="headingEndMark"> — </span>Intralesional corticosteroid injection involves the injection of a corticosteroid, such as <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide, directly into an inflamed nodule.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> –<strong> </strong>We typically use <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide at a concentration of 10 mg/mL and inject between 0.2 and 1 mL into individual nodules, with the amount injected dependent upon the size of the nodule. Noticeable improvement in symptoms often occurs within one to two days. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> –<strong> </strong>A prospective series of 36 patients with HS designed to assess the effect of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 10 mg/mL (volume range 0.2 to 2 mL) injected into an acute nodule or abscess had findings in support of a beneficial effect [<a href="#rid55">55</a>]. Mean pain, measured on a visual analog scale (VAS) from 0 to 10, where 10 represents greatest pain, decreased from 5.5 pretreatment to 1.1 at follow-up after a mean of seven days. Significant differences in pain VAS were found between days 0 and 1 and also from days 1 to 2 after the injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> –<strong> </strong>Cutaneous atrophy and other adverse effects of intralesional corticosteroid therapy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p></p><p class="headingAnchor" id="H2004775509"><span class="h3">Punch debridement</span><span class="headingEndMark"> — </span>Surgical unroofing is a procedure in which the skin overlying an inflamed nodule or skin tunnel is removed, and the resulting wound is allowed to heal via secondary intention. Punch debridement (partial unroofing) is a minor subtype of surgical unroofing that consists of utilization of a punch biopsy tool to evacuate acute, inflamed nodules that are centered around a single folliculopilosebaceous unit. Use of this technique is based upon clinical experience. The technique of punch debridement is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'Punch debridement'</a>.)</p><p class="headingAnchor" id="H3076839373"><span class="h3">Topical resorcinol</span><span class="headingEndMark"> — </span>Resorcinol is a topical chemical peeling agent with keratolytic and anti-inflammatory properties that is used by some clinicians for HS, where available.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Patients can be instructed to apply a thin film of resorcinol 15% cream directly to a new inflamed nodule twice daily. Resorcinol is <strong>not</strong> applied to the entire region. As improvement occurs, the frequency of application may be tapered to once daily, and application to the site of the inflamed nodule can be discontinued upon resolution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and precautions</strong> – Data on resorcinol in HS are limited. In an open study of 12 patients with Hurley stage I or II HS who applied topical 15% resorcinol once to twice daily primarily during disease flares, all patients experienced a reduction in pain and a reduction in duration of painful abscesses [<a href="#rid56">56</a>]. The expected adverse effect of local desquamation occurred in all patients. Recurrences may follow discontinuation of the medication.</p><p></p><p class="headingAnchor" id="H2586095199"><span class="h3">Incision and drainage</span><span class="headingEndMark"> — </span>Incision and drainage may promote lesion recurrence and is not advised for the routine treatment of acute lesions of HS. The procedure should be limited to situations in which immediate relief of severe pain from an inflamed, fluctuant nodule is necessary and treatment with other techniques is not feasible. (See  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'Role of I&amp;D'</a>.)</p><p class="headingAnchor" id="H5758489"><span class="h1">INFLAMMATORY LESIONS WITH SKIN TUNNELS OR SCARRING (HURLEY STAGE II OR III, MODERATE TO SEVERE DISEASE)</span><span class="headingEndMark"> — </span>The management of HS with inflammatory nodules plus skin tunnel formation or scarring involves medical and surgical interventions to reduce disease burden and improve acute, symptomatic lesions. In addition, surgical intervention is useful for findings that tend to have insufficient responses to medical therapy, such as skin tunnels and recurring nodules. Surgery is also used in the management of severe, refractory disease. (See <a class="local">'Reducing burden of disease'</a> below and <a class="local">'Acute, symptomatic lesions'</a> below and <a class="local">'Skin tunnels and recurrent nodules'</a> below.)</p><p class="headingAnchor" id="H938111178"><span class="h2">Reducing burden of disease</span><span class="headingEndMark"> — </span>The major interventions for reducing burden of disease in HS associated with inflammatory nodules, skin tunnels, and scarring include systemic therapies (eg, antibiotics, hormonal therapies, immunomodulatory drugs, or <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>) and wide local excision.</p><p class="headingAnchor" id="H1887524936"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>The initial treatment approach often consists of oral antibiotic therapy, usually oral tetracyclines or combination of oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). Antiandrogens (for female patients) or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> are commonly added as adjunctive therapies. (See <a class="local">'Oral tetracyclines'</a> below and <a class="local">'Clindamycin and rifampin'</a> below and <a class="local">'Metformin, oral contraceptives, and spironolactone'</a> below.)</p><p class="headingAnchor" id="H4116839130"><span class="h4">Oral tetracyclines</span><span class="headingEndMark"> — </span>Tetracyclines are our initial choice for antibiotic therapy for patients who present towards the moderate degree of the severity spectrum, with findings consistent with Hurley stage II disease. </p><p>Oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> therapy for moderate to severe disease is administered similarly to milder disease. When the response to tetracyclines is poor, we proceed to other therapies (eg, oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, or <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>)  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). (See <a class="local">'Oral tetracyclines'</a> above and <a class="local">'Clindamycin and rifampin'</a> below and <a class="local">'Failure of initial therapy'</a> below.)</p><p class="headingAnchor" id="H10646808"><span class="h4">Clindamycin and rifampin</span><span class="headingEndMark"> — </span>Combination therapy with oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is our preferred initial antibiotic regimen for HS presenting with extensive, inflammatory disease  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – A typical course is <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (at a dose of 300 mg twice daily) and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (at a dose of 300 mg twice daily) for 10 to 12 weeks. Responses are usually evident within this period. If the response is satisfactory, we stop the antibiotics and follow the patient for recurrence of disease activity  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). If the response is poor, we proceed to other treatments. If there is progressive improvement and the patient is tolerating treatment, we often continue treatment for up to an additional two to three months prior to reassessing the response to treatment.</p><p></p><p class="bulletIndent1">Use of oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> alone has also been proposed based upon a retrospective study of 60 patients with HS that found similar responses in patients treated with clindamycin and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and patients treated with clindamycin alone [<a href="#rid57">57</a>]. However, additional study is necessary to confirm the relative efficacy and safety of this treatment strategy.</p><p></p><p class="bulletIndent1">The best approach to maintaining improvement in patients who respond to a course of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is unclear. Long-term treatment with clindamycin and rifampin has traditionally been avoided because of concern for adverse effects, leading to use of other therapies to maintain improvement. However, some authors have challenged avoidance of long-term treatment with clindamycin and rifampin based upon data that suggest the greatest risk for adverse effects occurs during the initial weeks of treatment [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Use of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> for HS is based upon uncontrolled studies [<a href="#rid59">59-62</a>]. In one of the largest studies that evaluated this regimen, 116 patients with primarily Hurley stage I and II HS were treated with clindamycin (at a dose of 300 mg twice daily) and rifampin (at a dose of 600 mg once daily) for 10 weeks [<a href="#rid59">59</a>]. Significant decreases in the Sartorius score were observed, from a median of 28 points at baseline to 19 points at the end of treatment, and 8 of the 70 patients (11 percent) who were available for the week 10 assessments achieved complete remissions (Sartorius score of 0).</p><p></p><p class="bulletIndent1">In a separate retrospective study of 34 patients with stage I, II, or III HS who had failed various other treatments, 16 (47 percent) achieved a complete response (defined as &gt;75 percent improvement) to <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> administered via various treatment regimens [<a href="#rid60">60</a>]. However, the long-term benefit of treatment after treatment cessation was variable. In the study, 8 of 13 patients (62 percent) who responded completely to a regimen of clindamycin 300 mg twice daily and rifampin 300 mg twice daily (including nine patients treated for ≥10 weeks) relapsed after an average of five months. In a separate prospective case series of 26 patients with HS, treatment with clindamycin (at a dose of 300 mg twice daily) and rifampin (at a dose of 600 mg per day) for 12 weeks was associated with a clinical response (defined as at least 50 percent clinical improvement) in 19 patients (73 percent) [<a href="#rid62">62</a>]. Relapse did not occur in 7 of the 17 responders (41 percent) available for follow-up one year after treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Gastrointestinal adverse effects of this treatment regimen are common [<a href="#rid59">59,60</a>]. While the potential for <em>Clostridioides</em> <em>difficile</em> infection related to <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> therapy exists, in practice, it seems to be rare in patients with HS. Enzyme induction by <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> may reduce circulating concentrations of clindamycin, reducing risk for <em>C. difficile</em> infection [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Antibiotic use'</a>.)</p><p></p><p class="bulletIndent1">Patients should also be advised that <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> causes orange discoloration of bodily secretions, and the effectiveness of hormonal contraception is reduced. Acute renal failure (usually with a favorable prognosis) and liver injury are additional potential adverse effects. Drug interactions due to rifampin should be carefully reviewed. (See  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H4097412019"><span class="h4">Metformin, oral contraceptives, and spironolactone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a>, oral contraceptives, and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> are typically used as adjunctive therapies in patients with moderate to severe HS  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). Some authors have suggested that female patients who experience flares of HS in association with menses or have features of polycystic ovary syndrome may be more likely to benefit from antiandrogenic drugs [<a href="#rid22">22</a>]. We tend to use metformin in patients with obesity because the drug also promotes modest weight loss. Treatment regimens are similar to patients with less severe manifestations. (See <a class="local">'Metformin'</a> above and <a class="local">'Antiandrogenic agents'</a> above.)</p><p class="headingAnchor" id="H4267865231"><span class="h3">Failure of initial therapy</span><span class="headingEndMark"> — </span>Reasonable, subsequent medical treatment options for patients with HS presenting with inflammatory lesions, skin tunnels, and scarring who do not achieve satisfactory, sustained disease control with antibiotic therapy, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, or antiandrogenic therapy include the biologic tumor necrosis factor (TNF) inhibitors <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, the interleukin (IL) 17A inhibitor <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, and oral <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> (in patients of nonchildbearing potential)  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">Etanercept</a>, another TNF-alpha inhibitor, does not appear effective for HS [<a href="#rid63">63</a>].</p><p>Selection among these therapies is based upon consideration of efficacy data, risk for adverse effects, patient preference, and drug availability. <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a> is our preferred initial biologic agent based upon high-quality data to support efficacy in HS and the long-term safety data available for adalimumab use for other indications  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). Adalimumab is approved by the US Food and Drug Administration (FDA) and the European Commission for the treatment of HS.</p><p>Given limited efficacy data, we primarily reserve <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> for patients who prefer to avoid or cannot tolerate biologic therapy. (See <a class="local">'Acitretin'</a> below.)</p><p>The response to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> and other biologic therapies can generally be assessed after 12 to 16 weeks of treatment. If there is no evidence of response, we typically discontinue the biologic drug and proceed to other therapies  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). If there is a partial response, we often add other HS therapies (eg, antibiotics, antiandrogens, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>) to the biologic agent prior to considering a switch to a different biologic therapy. (See <a class="local">'Failure of adalimumab'</a> below.)</p><p class="headingAnchor" id="H2095201260"><span class="h4">Adalimumab</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The recommended dosing schedule for adults with HS is an initial 160 mg subcutaneous dose (given at one time or split into two 80 mg doses given over two consecutive days), then 80 mg on day 15, and then 40 mg once weekly starting on day 29 [<a href="#rid64">64</a>]. In 2020, FDA labeling for <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> was updated to include 80 mg every other week as an alternative to 40 mg weekly [<a href="#rid64">64</a>]. Given the larger body of evidence to support the 40 mg once-weekly regimen, we typically prescribe 40 mg once weekly [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">The recommended dosing regimen for adolescents 12 years of age and older who weigh less than 60 kg differs from adult dosing. Adolescents weighing 30 to 60 kg are treated with 80 mg on day 1 and 40 mg on day 8, followed by 40 mg <strong>every other week</strong>. Adolescents weighing at least 60 kg are treated with the same regimen as adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The FDA approval of <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> for moderate to severe HS was based upon the results of two similar phase 3, randomized trials (PIONEER I [n = 307] and PIONEER II [n = 326]). Patients with moderate to severe HS were randomly assigned either to adalimumab (at a dose of 40 mg once weekly) or placebo for the initial 12 weeks (period 1) [<a href="#rid65">65</a>]. This was followed by a 24-week phase (period 2) in which patients who received adalimumab in period 1 were randomly assigned to adalimumab weekly, adalimumab every other week, or placebo. Patients who received placebo in period 1 were reassigned to adalimumab weekly in PIONEER I and to placebo in PIONEER II. Patients in PIONEER II were allowed to continue oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> therapy at stable doses.</p><p></p><p class="bulletIndent1">At week 12, more patients in the <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> groups achieved the Hidradenitis Suppurativa Clinical Response (HiSCR) primary efficacy endpoint (≥50 percent reduction in the total abscess and inflammatory nodule count with no increase in the abscess or draining tunnel count) than in the placebo groups (42 versus 26 percent in PIONEER I and 59 versus 28 percent in PIONEER II). In addition, in PIONEER II but not PIONEER I, adalimumab treatment was associated with improvement in the secondary outcomes of lesion count, pain score, and the modified Sartorius score for disease severity at week 12.</p><p></p><p class="bulletIndent1">The response to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> declined in period 2. Among patients who responded to adalimumab in period 1, no significant difference in clinical response rates was detected between patients who received adalimumab versus placebo in period 2. The protocol-mandated cessation of treatment for patients who lost 50 percent or more of the improvement gained during period 1 (even if due to a temporary disease fluctuation) may have contributed to this result. A three-year, open-label, extension study that followed the PIONEER trials suggests long-term efficacy and safety of adalimumab [<a href="#rid66">66</a>]. The study found a sustained rate of response (achievement of HiSCR) over time among patients who received 40 mg of adalimumab once weekly for at least 60 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Examples of common adverse effects of <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> include injection site reactions and increased risk for infection. Adverse effects of adalimumab and other TNF inhibitors are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adalimumab</strong><strong> biosimilars</strong> – <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a> biosimilars, drugs that are highly similar to adalimumab, are associated with lower cost of treatment compared with adalimumab. However, the relative efficacy of adalimumab biosimilars compared with adalimumab is unclear. (See  <a class="medical medical_review" href="/z/d/html/3970.html" rel="external">"Overview of therapeutic monoclonal antibodies", section on 'Biosimilar mAbs'</a>.)</p><p></p><p class="bulletIndent1">Efficacy data for various <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> biosimilars in HS are primarily limited to retrospective studies with varying outcomes, including some studies that suggest a reduction in efficacy after switching from adalimumab to an adalimumab biosimilar [<a href="#rid13">13,67-70</a>]. Randomized trials in HS are necessary to confirm whether the efficacy of any adalimumab biosimilars are equivalent to adalimumab for HS.</p><p></p><p class="headingAnchor" id="H3485251961"><span class="h4">Acitretin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> is the primary oral retinoid utilized for HS; however, it should be avoided in patients of childbearing potential [<a href="#rid38">38</a>]. (See <a class="local">'Other oral retinoids'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Optimal dosing for <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> for HS is not established. We typically initiate treatment with a dose of 25 mg per day in adults. Initial signs of improvement are expected within the first two months of treatment [<a href="#rid71">71,72</a>].</p><p></p><p class="bulletIndent1">If significant improvement does not occur after 12 to 16 weeks and the patient is tolerating therapy, we increase the dose to 50 mg per day. If the response remains insufficient after 12 to 16 weeks, we proceed to other treatments.</p><p></p><p class="bulletIndent1">Combining oral retinoid therapy and treatment with tetracyclines is not recommended due to risk for idiopathic intracranial hypertension (pseudotumor cerebri). Oral retinoid therapy is contraindicated during, and for certain periods following, pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A prospective, uncontrolled study of 17 patients with HS treated with <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> (mean dose of 0.56 mg/kg/day) found a clinical response (at least 50 percent decrease in the HS Severity Index score after six months of treatment) in 8 of the 14 patients who attended for follow-up [<a href="#rid71">71</a>]. Only nine patients completed the planned nine months of therapy. The primary reasons for withdrawal from the study were treatment inefficacy and nonserious side effects.</p><p></p><p class="bulletIndent1">A retrospective study of 12 patients with recalcitrant Hurley stage II or III HS treated with <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> (mean dose 0.6 mg/kg daily) for 9 to 12 months with or without topical therapy found that all patients improved and that nine patients achieved marked or complete remissions [<a href="#rid72">72</a>]. The first initial signs of improvement were noted within approximately two months. Improvement often persisted after treatment, with nine patients maintaining responses for 6 to 45 months after the cessation of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Examples of common adverse effects of systemic retinoids include cheilitis, xerosis, and hyperlipidemia [<a href="#rid73">73</a>]. For additional information, refer to the <a class="external" href="/drug-interactions">drug interactions tool</a> included within UpToDate.</p><p></p><p class="bulletIndent1">Retinoids are teratogenic and must be avoided in individuals who are at risk for pregnancy or pregnant. Pregnancy should also be avoided for five weeks following <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a> treatment and for three years after <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>. Thus, the use of acitretin is typically avoided in females of childbearing potential, which limits its use for HS in the context that the highest prevalence of HS is in young adult females. In the United States, isotretinoin can only be prescribed through the iPLEDGE program, an internet-based risk management program. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'iPLEDGE program'</a>.)</p><p></p><p class="headingAnchor" id="H3811267334"><span class="h3">Failure of adalimumab</span><span class="headingEndMark"> — </span>Patients who do not experience sufficient improvement in HS with <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> or who cannot tolerate adalimumab may benefit from other therapies  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> is our preferred next treatment due to efficacy data from larger, randomized trials. Efficacy data for <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> are less robust.</p><p class="headingAnchor" id="H3248748219"><span class="h4">Secukinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> is a human monoclonal antibody that inhibits IL-17A. In 2023, the FDA, European Medicines Agency (EMA), and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved secukinumab for adults with active, moderate to severe HS [<a href="#rid74">74</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The suggested dosing for <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> is 300 mg at weeks 0, 1, 2, 3, and 4 followed by once-monthly maintenance dosing [<a href="#rid74">74</a>]. The frequency of dosing may be increased to every two weeks based upon clinical response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Data from two similar phase 3 trials support benefit of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> in HS. In the two trials (SUNSHINE trial [n = 541] and SUNRISE trial [n = 543]), adults with moderate to severe HS were randomly assigned to receive secukinumab 300 mg every two weeks, secukinumab 300 mg every four weeks, or placebo [<a href="#rid75">75</a>]. Every-two-week and every-four-week doses of secukinumab began after completion of a loading dose of 300 mg at weeks 0, 1, 2, 3, and 4. The trial included daily use of nonprescription topical antiseptics in all groups and permitted continuation of stable antibiotic therapy and initiation of rescue therapy (oral antibiotics, intralesional corticosteroid injection, or incision and drainage). At week 16, patients initially assigned to the placebo group were randomly reassigned to either the secukinumab every-two-weeks group or secukinumab every-four-weeks group.</p><p></p><p class="bulletIndent1">In the SUNSHINE trial, achievement of HiSCR was more frequent in the <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> two-weeks group compared with the placebo group (45 versus 34 percent, odds ratio 1.8, 95% CI 1.1-2.7), but the difference between the secukinumab every-four-weeks group and placebo group was not statistically significant (42 versus 34 percent, 95% CI 1.0-2.3). In the SUNRISE trial, achievement of HiSCR was more frequent in both the secukinumab every-two-weeks group (42 versus 31 percent, odds ratio 1.6, 95% CI 1.1-2.6) and secukinumab every-four-weeks group (46 versus 31 percent, odds ratio 1.9, 95% CI 1.2-3.0) compared with the placebo group. Secukinumab therapy was generally well tolerated. Serious adverse events were infrequent and occurred at a similar frequency across the groups. In the SUNSHINE trial, fungal infections occurred more frequently in the secukinumab every-two-weeks group than in the secukinumab every-four-weeks group. Across both trials, a total of three new cases of new-onset inflammatory bowel disease were detected through 52 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Examples of adverse effects of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> include increased risk for infections. Onset of inflammatory bowel disease during secukinumab therapy has been reported but appears to be uncommon [<a href="#rid75">75,76</a>]. (See  <a class="drug drug_general" href="/z/d/drug information/99569.html" rel="external">"Secukinumab: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H1277291912"><span class="h4">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> is an intravenously administered biologic TNF-alpha inhibitor.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The optimal regimen for <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for HS is unclear. We typically treat with a dosing regimen similar to the standard regimen for psoriasis (a dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks). However, there are clinical observations that suggest that more frequent dosing than used for psoriasis may be beneficial for HS, such as 5 mg/kg at weeks 0, 2, 6 and then every 4 weeks, rather than every 8 weeks [<a href="#rid77">77</a>]. Dosing of 10 mg/kg every four to eight weeks has been suggested by some experts [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Prospective studies on <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> therapy are limited [<a href="#rid78">78</a>]. A beneficial effect of infliximab for HS was demonstrated in a trial of 38 patients with moderate to severe HS [<a href="#rid79">79</a>]. During the initial randomized, double-blind phase of the trial, patients were treated with either infliximab infusions (at a dose of 5 mg/kg on weeks 0, 2, and 6) or placebo infusions. This phase was followed by an open-label phase in which patients in the infliximab group received maintenance doses of infliximab at weeks 14 and 22, and patients in the placebo group were given the opportunity to receive infliximab according to the same treatment regimen. By week 8, there was not a significant difference between the treatment and placebo groups for the primary study outcome (≥50 percent decrease in an unvalidated disease severity score) [<a href="#rid63">63,79</a>]. However, infliximab therapy was associated with statistically significant improvements in patient quality of life, pain, and physician global assessment scores. On physician global assessment, 47 percent of patients in the infliximab group attained 75 to 99 percent improvement compared with none of the patients treated with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Examples of adverse effects of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> include infusion reactions and increased risk for infection. Adverse effects are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H359944446"><span class="h3">Severe, refractory disease</span><span class="headingEndMark"> — </span>For patients with severe, refractory (Hurley stage III) disease, wide excision can be beneficial in conjunction with medical therapy  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3322448890"><span class="h4">Wide excision</span><span class="headingEndMark"> — </span>Extensive surgical intervention is considered to offer the greatest likelihood for the resolution of active inflammation in the treated area [<a href="#rid80">80</a>]. Of note, the procedure can be disfiguring and involve a prolonged recovery time. In addition, extensive excision of all affected sites is not usually feasible in patients with multiple affected skin regions. (See  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'General considerations'</a>.)</p><p>Data to support wide excision are limited and primarily consist of data from uncontrolled studies [<a href="#rid81">81</a>]. For example, in one retrospective study in which 31 patients were treated with drainage procedures, limited regional excisions, and wide excision and followed for a mean of 72 months, only 3 of 11 patients treated with wide excision experienced disease recurrence, with a median recurrence interval of 20 months [<a href="#rid82">82</a>]. In a study in which 499 patients who underwent surgical intervention for HS, including 88 treated with excisional procedures, were surveyed about their satisfaction with surgery, most patients (85 percent) were satisfied with the outcome of their surgical procedure [<a href="#rid83">83</a>].</p><p>Optimal control of HS inflammation prior to surgery is preferred, as it may improve surgical outcomes [<a href="#rid18">18</a>]. The surgical approach to wide excision is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'Local procedures'</a> and  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'Wide excision and reconstruction'</a>.)</p><p class="headingAnchor" id="H2545471649"><span class="h4">Medical therapies</span><span class="headingEndMark"> — </span>Patients with moderate to severe HS may respond to other systemic therapies generally reserved for disease refractory to standard approaches. Data from small, randomized trials or uncontrolled studies suggest benefit of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="138686" href="/z/d/drug information/138686.html" rel="external">bimekizumab</a>, and intravenous <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ustekinumab</strong><strong> </strong>– Positive responses to <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, an IL-12/23 inhibitor given via subcutaneous injection, have been reported in patients with moderate to severe, refractory HS [<a href="#rid84">84-86</a>]. An uncontrolled study in which 17 patients with Hurley stage II or III HS received 45 or 90 mg of ustekinumab at weeks 0, 4, 16, and 28 found at least a 50 percent reduction in the modified Sartorius score in six patients (35 percent) at week 40 and a 25 to 49 percent reduction in the modified Sartorius score in eight patients (47 percent) at week 40 [<a href="#rid86">86</a>]. Less improvement occurred in one patient, and two patients had no improvement. Limitations of this study include the small number of patients and a high premature dropout rate due to lack of response (three patients), withdrawal of informed consent (one patient), and an adverse event of urticaria (one patient).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anakinra</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a>, an antagonist of the IL-1 receptor, may be a treatment option for HS. A 24-week, randomized trial in which 20 adults with Hurley stage II or III HS were randomly assigned to subcutaneous injections of anakinra at a dose of 100 mg or placebo once daily for 12 weeks found reductions in the disease activity score in six of nine patients (67 percent) in the anakinra group compared with only 2 of 10 patients (20 percent) in the placebo group at the end of treatment [<a href="#rid87">87</a>]. One patient in the anakinra group was lost to follow-up. In addition, anakinra therapy was associated with prolongation of the time to which patients noticed a new exacerbation of HS. Changes in the Sartorius score, patient-reported disease severity, and quality of life did not differ between the anakinra and placebo groups. No serious adverse events occurred.</p><p></p><p class="bulletIndent1">Other reports of the effects of <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> on HS include a case series and a case report [<a href="#rid88">88,89</a>]. In the case series of six patients treated with eight weeks of anakinra (at a dose of 100 mg per day via subcutaneous injection) for moderate to severe HS, the five patients who completed the treatment course demonstrated reductions in the modified Sartorius score, physician and patient global assessment scores, and improvement in quality of life [<a href="#rid89">89</a>]. However, the effects of anakinra diminished upon treatment cessation, and rebound of disease was evident eight weeks after the end of treatment. In the case report, a female patient with refractory HS treated with anakinra (at a dose of 200 mg per day) achieved disease remission within one year with continued treatment [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">Failure to respond to <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> 100 mg per day has been reported [<a href="#rid90">90-92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bimekizumab</strong> – Data from a phase 2, randomized trial suggest benefit of the investigational drug <a class="drug drug_general" data-topicid="138686" href="/z/d/drug information/138686.html" rel="external">bimekizumab</a>, which inhibits both IL-17A and IL-17F. In the trial, 90 adults with moderate to severe HS were randomly assigned in a 2:1:1 ratio to receive bimekizumab (at a dose of 320 mg every two weeks after a 640 mg loading dose at baseline), placebo, or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> (at a dose of 40 mg per week after a 160 mg loading dose at baseline and 80 mg dose at week 2) over a 10-week period [<a href="#rid93">93</a>]. At week 12, more patients in the bimekizumab group achieved HiSCR than patients in the placebo group (57 versus 26 percent; posterior probability of superiority of 0.998 calculated using Bayesian analysis). Bimekizumab is not available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><strong>ertapenem</strong> – Patients with severe suppurative disease unresponsive to the oral combination of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> may require rescue therapy with intravenous antibiotics. Intravenous <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a> at a dose of 1 g daily for six weeks was associated with a reduction in disease severity in a retrospective study of 30 patients given ertapenem for severe HS [<a href="#rid94">94</a>]. Local antibiotic stewardship policies should be reviewed prior to use of this regimen.</p><p></p><p>Additional agents for which benefit is suggested in case series or case reports include <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> [<a href="#rid95">95</a>], <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> [<a href="#rid96">96</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid97">97-100</a>], and oral <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid101">101</a>]. Data from a small, randomized trial and uncontrolled study suggest that bermekimab, an IL-1-alpha inhibitor, may also be an effective therapy [<a href="#rid102">102,103</a>]. Bermekimab is not commercially available.</p><p class="headingAnchor" id="H3273499610"><span class="h2">Acute, symptomatic lesions</span><span class="headingEndMark"> — </span>Individual acute, inflammatory nodules may be managed similarly as lesions in the setting of less severe disease  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). (See <a class="local">'Acute, symptomatic lesions'</a> above.)</p><p>Systemic glucocorticoids are an additional option for treating highly symptomatic, acute flares. Based upon clinical experience, a three- to four-day course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg per day, tapered over the subsequent 7 to 10 days, is often sufficient for acutely managing inflammation. We reserve systemic glucocorticoids for rescue therapy to treat severe flares resistant to antibiotic therapy as a bridge to other therapies. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H1241363568"><span class="h2">Skin tunnels and recurrent nodules</span><span class="headingEndMark"> — </span>Skin tunnels are persistent, often draining, subcutaneous structures that tend to form in the setting of multiple recurrent nodules within a localized region. Skin tunnels require surgical intervention for resolution.</p><p>Surgical unroofing (also known as deroofing) involves removal of skin overlying skin tunnels or nodules followed by healing by secondary intention. Uncontrolled studies and reports of clinical experience suggest efficacy of surgical deroofing procedures for skin tunnels and recurrent nodules [<a href="#rid104">104-108</a>]. In one study of 88 deroofed lesions in 44 patients with HS, 73 lesions (83 percent) did not recur after a median follow-up of 34 months [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'Unroofing (local or extensive)'</a>.)</p><p>Wide excision is an alternative approach for skin tunnels and nodules in the setting of severe, extensive HS. (See <a class="local">'Wide excision'</a> above.)</p><p class="headingAnchor" id="H739287834"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1961300501"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>The majority of patients with HS experience no change or improvement in symptoms during pregnancy, while a minority experience worsening disease [<a href="#rid109">109</a>]. HS may flare in the postpartum period.</p><p>There are safety concerns with most of the systemic therapies utilized for HS. The risks and benefits of therapy should be carefully considered on an individual basis. Oral retinoids are contraindicated in pregnancy.</p><p class="headingAnchor" id="H2844109907"><span class="h2">Children</span><span class="headingEndMark"> — </span>Children and adolescents with HS are treated with many of the therapies commonly used for adult disease [<a href="#rid110">110,111</a>]. Topical <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and oral antibiotics (eg, tetracyclines, oral clindamycin alone or in combination with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>) are common initial therapies. Of note, tetracyclines are not recommended for children under the age of nine due to the potential drug-induced discoloration of permanent teeth.</p><p>Other agents that have been used for pediatric HS include <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, short courses of oral glucocorticoids, <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (females), biologic tumor necrosis factor (TNF) inhibitors (<a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>), and surgery [<a href="#rid110">110,111</a>].</p><p class="headingAnchor" id="H1985432581"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span>Other therapies may be beneficial in HS. Examples include neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy, <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, and zinc supplementation.</p><p class="headingAnchor" id="H4183285023"><span class="h2">Nd:YAG laser</span><span class="headingEndMark"> — </span>In a randomized, within-participant trial of 22 patients with Hurley stage II or III disease, treatment of the affected skin region with a 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser reduced disease severity in inguinal, axillary, and inframammary sites [<a href="#rid112">112</a>]. The mechanism of action of the Nd:YAG laser in HS may involve follicular destruction or dermal heating leading to the disruption of the inflammatory infiltrate [<a href="#rid113">113</a>]. Intense pulsed light is an alternative modality targeting the hair follicle [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H100309147"><span class="h2">Rifampin, moxifloxacin, and metronidazole</span><span class="headingEndMark"> — </span>Combination therapy with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>, and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> has appeared beneficial in uncontrolled studies. In a retrospective study of 28 patients with longstanding HS that was refractory to other treatments (short-course antimicrobials, surgical drainage, and/or surgical excision), treatment with these drugs was associated with reduced disease activity [<a href="#rid115">115</a>]. Patients with stage I or II HS appeared to benefit most from this intervention.</p><p>In addition, in a prospective, uncontrolled study, 28 patients with Hurley stage I HS were given a six-week course of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (at a dose of 10 mg/kg once daily), <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> (at a dose of 400 mg once daily [or 1 g of pristinamycin three times daily if concern for poor tolerance of moxifloxacin]), and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (at a dose of 250 or 500 mg three times daily), followed by rifampin and moxifloxacin for four weeks and, if remission was obtained, given long-term prophylaxis with either cotrimoxazole (most patients) or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid116">116</a>]. At 12 weeks, 75 percent achieved clinical remission, and at the one year follow-up, flare rates had fallen from a median of 21 flares per year to 1 per year.</p><p>Some of the potential adverse effects of concern include risk for tendonitis or tendon rupture from <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>; orange body secretions and drug interactions from <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>; and alcohol-associated, disulfiram-like reactions and adverse neurologic effects from <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. For additional information, refer to the <a class="external" href="/drug-interactions">drug interactions tool</a> included within UpToDate.</p><p class="headingAnchor" id="H3286365570"><span class="h2">Apremilast</span><span class="headingEndMark"> — </span>Limited data suggest benefit of <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, a phosphodiesterase 4 inhibitor, for HS [<a href="#rid117">117,118</a>]. A trial in which 20 patients with moderate HS were randomly assigned to receive either 30 mg of apremilast twice daily (15 patients) or placebo (5 patients) found apremilast superior for achieving the Hidradenitis Suppurativa Clinical Response (HiSCR) primary efficacy endpoint (≥50 percent reduction in the total abscess and inflammatory nodule count with no increase in the abscess or draining sinus count) at week 16 [<a href="#rid117">117</a>]. In the apremilast group, 8 out of 15 patients (53 percent) achieved HiSCR compared with none of the patients in the placebo group. Apremilast was generally well tolerated. The most common adverse events among participants who received apremilast were headache, diarrhea, nausea, and the common cold. Additional study is necessary to confirm efficacy and safety of apremilast in the treatment of HS.</p><p class="headingAnchor" id="H2791314177"><span class="h2">Zinc supplementation</span><span class="headingEndMark"> — </span>Zinc salts have anti-inflammatory and antiandrogenic properties, and there are limited data for possible benefit in HS [<a href="#rid119">119</a>]. The efficacy of <a class="drug drug_general" data-topicid="96338" href="/z/d/drug information/96338.html" rel="external">zinc gluconate</a> 90 mg per day was investigated in a pilot study of 22 patients who had failed to achieve satisfactory improvement with systemic antibiotic therapy, antiandrogens, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, or surgery [<a href="#rid119">119</a>]. All but one patient had Hurley stage I or II disease. Among the patients, eight (36 percent) achieved complete responses (disappearance of lesions or no new lesions for ≥6 months), and the remainder achieved partial remissions (≥50 percent reduction in the number of nodules and/or a shorter duration of inflammatory lesions). However, relapses occurred upon tapering of the dose to ≤60 mg per day.</p><p>Additional support for a beneficial effect of <a class="drug drug_general" data-topicid="96338" href="/z/d/drug information/96338.html" rel="external">zinc gluconate</a> in HS stems from a prospective study of 12 patients with Hurley stage I or II HS [<a href="#rid120">120</a>]. Deficiencies in innate immune markers detected in lesional and nonlesional skin from patients with HS were improved following three months of treatment with zinc gluconate at a dose of 90 mg per day.</p><p>Gastrointestinal upset may occur as a consequence of <a class="drug drug_general" data-topicid="10328" href="/z/d/drug information/10328.html" rel="external">zinc sulfate</a> therapy [<a href="#rid119">119</a>]; <a class="drug drug_general" data-topicid="96338" href="/z/d/drug information/96338.html" rel="external">zinc gluconate</a> given as 30 mg twice or three times per day in adults may be better tolerated. Of note, zinc may displace copper, reducing copper absorption.</p><p class="headingAnchor" id="H4189228284"><span class="h2">Other oral retinoids</span><span class="headingEndMark"> — </span>In addition to <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and a newer oral retinoid, <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>, have been used to treat HS. (See <a class="local">'Acitretin'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isotretinoin</strong> – <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> remains the gold standard treatment for severe acne vulgaris and is often used to treat concomitant acne in patients with HS. However, it appears to provide only limited benefit for HS and may worsen the condition, so we avoid it in HS without acne.</p><p></p><p class="bulletIndent1">Studies of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy have demonstrated improvement in relatively low proportions of patients with HS. In a series of 88 patients treated with isotretinoin for an average of eight months (mean daily dose 44 mg/day, range = 20 to 140 mg per day), improvement was reported in only 14 patients (16 percent) [<a href="#rid121">121</a>]. In a retrospective study of 68 patients with various stages of HS who were treated for four to six months with isotretinoin (mean daily doses of 0.5 to 0.8 mg/kg), 16 (24 percent) achieved clearing of disease, and 25 showed lesser improvement [<a href="#rid122">122</a>]. All patients who cleared had disease that was mild or moderate in severity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alitretinoin</strong> – In a series of 14 patients with HS, treatment with <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a> (at a dose of 10 mg per day) for 24 weeks produced improvement in 11 patients (79 percent), including 6 who achieved significant improvement (at least 50 percent reduction in the Sartorius score) [<a href="#rid123">123</a>]. Alitretinoin is not available in the United States.</p><p></p><p class="headingAnchor" id="H643704579"><span class="h2">Other</span><span class="headingEndMark"> — </span>A number of other treatments have been proposed for HS. However, unclear efficacy or concern for adverse effects preclude recommendations for routine use of these interventions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fumarates</strong> – Fumarates are anti-inflammatory and immunomodulatory agents used in the treatment of psoriasis. In an uncontrolled, pilot study in which seven patients with treatment-refractory, moderate to severe HS were treated with oral fumarates, three patients seemed to improve during therapy, and four patients discontinued treatment because of lack of efficacy [<a href="#rid124">124</a>]. Data are insufficient to recommend routine use of this therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D3</strong> – <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">Vitamin D3</a> supplementation has been proposed as a treatment for HS based upon hypotheses that a deficiency in innate immunity may contribute to HS and that vitamin D3 may play an important role in innate immunity. In an uncontrolled study in which 14 patients with HS and vitamin D3 deficiency (defined as 25-hydroxyvitamin D3 level &lt;30 ng/mL) received vitamin D3 supplementation (administered as 100,000 to 600,000 international units given at baseline and/or after three months depending on the serum vitamin D level), 11 (79 percent) had at least a 20 percent reduction in the number of nodules after six months [<a href="#rid125">125</a>]. Additional study is necessary to confirm efficacy of vitamin D3 supplementation in HS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ionizing radiation</strong> – A retrospective study of 231 patients with refractory HS treated with radiotherapy found that 38 percent had complete resolution of symptoms, and an additional 40 percent had some degree of improvement in symptoms following radiation treatment [<a href="#rid126">126</a>]. Although radiation therapy administered to the affected skin region may be effective [<a href="#rid126">126,127</a>], this modality is rarely used for HS due to concern for the occurrence of long-term adverse effects (eg, chronic radiation dermatitis, ulceration, cutaneous malignancy) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/13668.html" rel="external">"Radiation dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/7055.html" rel="external">"Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photodynamic therapy</strong> – Photodynamic therapy combines use of a photosensitizer and a light source to induce cellular destruction through porphyrin activation. Treatment of areas of involvement of HS with photodynamic therapy using a topical photosensitizer has yielded variable results [<a href="#rid128">128-132</a>]. An intralesional technique for photodynamic therapy was associated with improvement in case reports and a small, retrospective study [<a href="#rid133">133,134</a>]. Intralesional photodynamic therapy is rarely used clinically.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Examples of treatments that have been reported as beneficial in case reports and small clinical studies include botulinum toxin injections [<a href="#rid135">135,136</a>], cryoinsufflation [<a href="#rid137">137</a>], <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a> [<a href="#rid138">138</a>], <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a> [<a href="#rid139">139,140</a>], Janus kinase (JAK) inhibitors [<a href="#rid141">141,142</a>], and the glucagon-like peptide-1 agonist <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> [<a href="#rid143">143</a>]. Further study will be useful for confirming the efficacy of these therapies.</p><p></p><p class="bulletIndent1">Microwave ablation, a noninvasive procedure that destroys sweat glands and hair follicles through thermolysis, is <strong>not</strong> recommended for HS. A randomized trial in which outcomes of a single treatment in one axilla were compared with findings in the untreated contralateral axilla was discontinued after interim analysis of nine patients suggested no benefit and potential harm of this intervention [<a href="#rid144">144</a>]. Of the eight patients who completed treatment, five experienced worsening of disease after treatment.</p><p></p><p class="headingAnchor" id="H22"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Early diagnosis of HS is essential because most cases can be effectively treated when diagnosed at an early stage [<a href="#rid19">19</a>]. Hurley stage III disease is very difficult to manage and requires a multidisciplinary treatment approach, with coordination between dermatologists, dermatology specialist nurses, surgeons who have axillary and inguinal expertise, wound healing experts, and input from clinical psychologists. Although cure is possible in a skin region after extensive surgery [<a href="#rid145">145</a>], this does not prevent disease progression in other affected skin regions and so further medical treatment may be required.</p><p class="headingAnchor" id="H1157503468"><span class="h1">RISK FOR SQUAMOUS CELL CARCINOMA</span><span class="headingEndMark"> — </span>Rarely, squamous cell carcinoma develops within sites of HS. Squamous cell carcinoma tends to be seen in patients who have suffered from HS for many years, particularly in the perianal region, and is often advanced at diagnosis [<a href="#rid146">146-149</a>]. Clinical signs suggestive of squamous cell carcinoma may include a new or rapidly growing, exophytic lesion or ulcer.</p><p class="headingAnchor" id="H318927924"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114775.html" rel="external">"Society guideline links: Hidradenitis suppurativa"</a>.)</p><p class="headingAnchor" id="H8926365"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83523.html" rel="external">"Patient education: Hidradenitis suppurativa (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1357267"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Hidradenitis suppurativa (HS) is a chronic, follicular, occlusive disease characterized by the development of inflammatory nodules, skin tunnels, and scars, primarily in intertriginous areas. Pain, chronic drainage, odor, and disfigurement are common features of this disorder. HS can have a profound, negative effect on quality of life. (See <a class="local">'Introduction'</a> above and <a class="local">'Goals of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment</strong> – Treatment of HS is generally indicated. The major goals of treatment are to reduce the formation of new inflammatory lesions, skin tunnels, and scarring; to treat existing lesions and reduce associated symptoms; and to minimize associated psychologic morbidity. (See <a class="local">'Goals of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment</strong> – The severity of HS influences the approach to treatment  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>). Features such as the extent of skin involvement and the presence of skin tunnels or scarring influence disease severity. The Hurley staging system is also used to define disease severity. (See <a class="local">'Assessment of disease severity and response'</a> above.)</p><p></p><p class="bulletIndent1">The management of HS involves multiple interventions. In addition to medical or surgical therapy to reduce disease burden and treat acute lesions or skin tunnels, patient education, psychologic support resources, wound care guidance, and pain management are important components of treatment. (See <a class="local">'Interventions for all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of acute, painful lesions</strong> – Patients with acute, painful, inflammatory nodules may benefit from interventions to accelerate improvement in symptoms in addition to interventions to improve the overall disease burden. Intralesional corticosteroid injections, punch debridement, or topical resorcinol may be used for this purpose. (See <a class="local">'Acute, symptomatic lesions'</a> above.)</p><p></p><p class="bulletIndent1">Incision and drainage <strong>is not</strong> advised for the routine treatment of acute lesions of HS. Incision and drainage should be restricted to situations in which immediate pain relief is necessary and other interventions for acute lesions are not feasible. (See <a class="local">'Incision and drainage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of skin tunnels or recurrent nodules</strong> –<strong> </strong>For patients with recurrent nodules or symptomatic or draining skin tunnels, we suggest a combination of medical and surgical therapy rather than medical therapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Surgical unroofing (also known as deroofing) involves removal of skin overlying skin tunnels or nodules followed by healing by secondary intention. Medical therapy can be insufficient for improving these lesions. (See <a class="local">'Skin tunnels and recurrent nodules'</a> above and  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical therapy to reduce disease activity</strong> – A variety of medical interventions have been used to reduce disease burden in HS. The approach to treatment selection is dependent upon the clinical presentation  (<a class="graphic graphic_algorithm graphicRef142448" href="/z/d/graphic/142448.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with inflammatory lesions without skin tunnels or scarring</strong> (Hurley stage I disease  (<a class="graphic graphic_picture graphicRef90463" href="/z/d/graphic/90463.html" rel="external">picture 2</a>))</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Initial medical therapy</strong> – We suggest an oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) rather than other therapies as the initial medical treatment for HS without skin tunnels or scarring (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with additional features that suggest benefit of hormonal therapy, we often add an oral contraceptive, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> to antibiotic therapy. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Refractory disease</strong> – Options for disease that does not respond sufficiently to tetracyclines include <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> combination therapy, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy. Treatment selection involves consideration of treatment-specific risks and patient preference. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with inflammatory lesions with skin tunnels or scarring</strong> (Hurley stage II or III disease  (<a class="graphic graphic_picture graphicRef90464 graphicRef139058 graphicRef90465 graphicRef65188" href="/z/d/graphic/90464.html" rel="external">picture 1A-D</a>))</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Initial medical therapy</strong> – For most patients, we suggest an oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) rather than other antibiotics as initial treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients presenting with extensive, inflammatory disease (eg, Hurley stage III HS), we suggest initial treatment with a combination of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> rather than tetracyclines (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Failure of initial medical therapy</strong> – For disease that has not responded to at least one oral antibiotic, we suggest <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> rather than other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Phase 3, randomized trials support efficacy of adalimumab, and long-term safety data for adalimumab use for other indications are available. (See <a class="local">'Failure of initial therapy'</a> above and <a class="local">'Adalimumab'</a> above.)</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> are acceptable alternatives to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> or later-line therapies for patients who did not improve sufficiently with adalimumab. Oral <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> is an alternative for patients who prefer to avoid or cannot tolerate biologic therapy and cannot become pregnant. In some locations, adalimumab biosimilars are commonly prescribed for HS to reduce the cost of biologic treatment, but some uncertainty remains about their efficacy compared with adalimumab treatment. (See <a class="local">'Failure of adalimumab'</a> above and <a class="local">'Secukinumab'</a> above and <a class="local">'Infliximab'</a> above and <a class="local">'Acitretin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe, refractory disease</strong> – For patients with severe HS refractory to antibiotics and biologic agents, options for treatment include surgical wide excision and medical therapies reserved for refractory disease, such as <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="138686" href="/z/d/drug information/138686.html" rel="external">bimekizumab</a>, intravenous <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>, and other treatments. (See <a class="local">'Severe, refractory disease'</a> above and  <a class="medical medical_review" href="/z/d/html/110073.html" rel="external">"Surgical management of hidradenitis suppurativa", section on 'Wide excision and reconstruction'</a>.)</p><p></p><p class="headingAnchor" id="H3145300181"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lynette Margesson, MD, FRCPC, FAAD, who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges F. William Danby, MD, FRCPC, FAAD, now deceased, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56:621.</a></li><li><a class="nounderline abstract_t">Senthilnathan A, Kolli SS, Cardwell LA, et al. Even mild hidradenitis suppurativa impairs quality of life. Br J Dermatol 2019; 181:838.</a></li><li><a class="nounderline abstract_t">Storer MA, Danesh MJ, Sandhu ME, et al. An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. Int J Womens Dermatol 2018; 4:198.</a></li><li><a class="nounderline abstract_t">Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90:264.</a></li><li><a class="nounderline abstract_t">Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91:328.</a></li><li><a class="nounderline abstract_t">Kurek A, Peters EM, Chanwangpong A, et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 2012; 67:422.</a></li><li><a class="nounderline abstract_t">Jalenques I, Ciortianu L, Pereira B, et al. The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis. J Am Acad Dermatol 2020; 83:542.</a></li><li class="breakAll">Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: Surgical approach. In: Dermatologic Surgery, Roenigk RK, Roenigk HH (Eds), Dekker, 1989. p.729.</li><li><a class="nounderline abstract_t">Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 2020; 183:340.</a></li><li><a class="nounderline abstract_t">Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210.</a></li><li><a class="nounderline abstract_t">Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5:105.</a></li><li><a class="nounderline abstract_t">Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014; 171:1434.</a></li><li><a class="nounderline abstract_t">Montero-Vilchez T, Cuenca-Barrales C, Rodriguez-Tejero A, et al. Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177:1401.</a></li><li><a class="nounderline abstract_t">Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol 2018; 179:642.</a></li><li><a class="nounderline abstract_t">Thorlacius L, Ingram JR, Garg A, et al. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open 2017; 7:e014733.</a></li><li><a class="nounderline abstract_t">Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 2019; 180:1009.</a></li><li><a class="nounderline abstract_t">Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 2019; 81:76.</a></li><li><a class="nounderline abstract_t">Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015; 173:1546.</a></li><li><a class="nounderline abstract_t">Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol 2020; 82:366.</a></li><li><a class="nounderline abstract_t">Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013; 27:473.</a></li><li><a class="nounderline abstract_t">Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol 2019; 81:91.</a></li><li><a class="nounderline abstract_t">Reddy S, Orenstein LAV, Strunk A, Garg A. Incidence of Long-term Opioid Use Among Opioid-Naive Patients With Hidradenitis Suppurativa in the United States. JAMA Dermatol 2019; 155:1284.</a></li><li><a class="nounderline abstract_t">Miller IM, McAndrew RJ, Hamzavi I. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol Clin 2016; 34:7.</a></li><li><a class="nounderline abstract_t">Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71:1144.</a></li><li><a class="nounderline abstract_t">Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol 2022; 86:1092.</a></li><li><a class="nounderline abstract_t">Soliman YS, Chaitowitz M, Hoffman LK, et al. Identifying anaemia in a cohort of patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020; 34:e5.</a></li><li><a class="nounderline abstract_t">Dauden E, Lazaro P, Aguilar MD, et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2018; 32:129.</a></li><li><a class="nounderline abstract_t">Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161:831.</a></li><li><a class="nounderline abstract_t">Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366:158.</a></li><li><a class="nounderline abstract_t">Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59:596.</a></li><li><a class="nounderline abstract_t">Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61:51.</a></li><li><a class="nounderline abstract_t">König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198:261.</a></li><li><a class="nounderline abstract_t">Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol 2016; 152:429.</a></li><li><a class="nounderline abstract_t">Kromann CB, Ibler KS, Kristiansen VB, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 2014; 94:553.</a></li><li><a class="nounderline abstract_t">Simonart T. Hidradenitis suppurativa and smoking. J Am Acad Dermatol 2010; 62:149.</a></li><li><a class="nounderline abstract_t">Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011; 672:1.</a></li><li><a class="nounderline abstract_t">Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29:619.</a></li><li><a class="nounderline abstract_t">Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39:971.</a></li><li><a class="nounderline abstract_t">Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115:263.</a></li><li><a class="nounderline abstract_t">Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11:125.</a></li><li><a class="nounderline abstract_t">Lee A, Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol 2015; 56:192.</a></li><li><a class="nounderline abstract_t">Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 2005; 16:75.</a></li><li><a class="nounderline abstract_t">Farrell AM, Randall VA, Vafaee T, Dawber RP. Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol 1999; 141:1138.</a></li><li><a class="nounderline abstract_t">Mota F, Machado S, Selores M. Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series. Pediatr Dermatol 2017; 34:578.</a></li><li><a class="nounderline abstract_t">Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2019; 80:114.</a></li><li><a class="nounderline abstract_t">Quinlan C, Kirby B, Hughes R. Spironolactone therapy for hidradenitis suppurativa. Clin Exp Dermatol 2020; 45:464.</a></li><li><a class="nounderline abstract_t">Khandalavala BN, Do MV. Finasteride in Hidradenitis Suppurativa: A "Male" Therapy for a Predominantly "Female" Disease. J Clin Aesthet Dermatol 2016; 9:44.</a></li><li><a class="nounderline abstract_t">Verdolini R, Clayton N, Smith A, et al. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 2013; 27:1101.</a></li><li><a class="nounderline abstract_t">Jennings L, Hambly R, Hughes R, et al. Metformin use in hidradenitis suppurativa. J Dermatolog Treat 2020; 31:261.</a></li><li><a class="nounderline abstract_t">Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22:325.</a></li><li><a class="nounderline abstract_t">Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 2011; 222:342.</a></li><li><a class="nounderline abstract_t">Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat 2006; 17:211.</a></li><li><a class="nounderline abstract_t">Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012; 92:194.</a></li><li><a class="nounderline abstract_t">Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. J Am Acad Dermatol 2016; 75:1151.</a></li><li><a class="nounderline abstract_t">Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010; 35:36.</a></li><li><a class="nounderline abstract_t">Caposiena Caro RD, Cannizzaro MV, Botti E, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations. J Am Acad Dermatol 2019; 80:1314.</a></li><li><a class="nounderline abstract_t">Albrecht J, Baine PA, Ladizinski B, et al. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic. Br J Dermatol 2019; 180:749.</a></li><li><a class="nounderline abstract_t">Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219:148.</a></li><li><a class="nounderline abstract_t">van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219:143.</a></li><li><a class="nounderline abstract_t">Mendonça CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006; 154:977.</a></li><li><a class="nounderline abstract_t">Dessinioti C, Zisimou C, Tzanetakou V, et al. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol 2016; 41:852.</a></li><li><a class="nounderline abstract_t">Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev 2015; :CD010081.</a></li><li class="breakAll">Adalimumab injection, for subcutaneous use. US Food and Drug Administration (FDA) approved product information. Revised December 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s418s419lbl.pdf (Accessed on January 05, 2021).</li><li><a class="nounderline abstract_t">Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375:422.</a></li><li><a class="nounderline abstract_t">Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019; 80:60.</a></li><li><a class="nounderline abstract_t">Burlando M, Fabbrocini G, Marasca C, et al. Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study. Biomedicines 2022; 10.</a></li><li><a class="nounderline abstract_t">Grau-Pérez M, Rodríguez-Aguilar L, Roustan G, Alfageme F. Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study. J Eur Acad Dermatol Venereol 2023; 37:e678.</a></li><li><a class="nounderline abstract_t">Roccuzzo G, Rozzo G, Burzi L, et al. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness? Dermatol Ther 2022; 35:e15803.</a></li><li><a class="nounderline abstract_t">Kirsten N, Ohm F, Gehrdau K, et al. Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest. Life (Basel) 2022; 12.</a></li><li><a class="nounderline abstract_t">Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol 2014; 171:170.</a></li><li><a class="nounderline abstract_t">Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 2011; 164:170.</a></li><li><a class="nounderline abstract_t">Danby FW. Night blindness, vitamin A deficiency, and isotretinoin psychotoxicity. Dermatol Online J 2003; 9:30.</a></li><li class="breakAll">Secukinumab. European Medicines Agency (EMA) summary of product characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf (Accessed on June 06, 2023).</li><li><a class="nounderline abstract_t">Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023; 401:747.</a></li><li><a class="nounderline abstract_t">Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019; 78:473.</a></li><li><a class="nounderline abstract_t">Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol 2014; 170:986.</a></li><li><a class="nounderline abstract_t">Shih T, Lee K, Grogan T, et al. Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis. Dermatol Ther 2022; 35:e15691.</a></li><li><a class="nounderline abstract_t">Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62:205.</a></li><li><a class="nounderline abstract_t">Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg 2012; 38:517.</a></li><li><a class="nounderline abstract_t">Kohorst JJ, Baum CL, Otley CC, et al. Surgical Management of Hidradenitis Suppurativa: Outcomes of 590 Consecutive Patients. Dermatol Surg 2016; 42:1030.</a></li><li><a class="nounderline abstract_t">Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998; 13:164.</a></li><li><a class="nounderline abstract_t">Kohorst JJ, Baum CL, Otley CC, et al. Patient Satisfaction and Quality of Life Following Surgery for Hidradenitis Suppurativa. Dermatol Surg 2017; 43:125.</a></li><li><a class="nounderline abstract_t">Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92:320.</a></li><li><a class="nounderline abstract_t">Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26:911.</a></li><li><a class="nounderline abstract_t">Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174:839.</a></li><li><a class="nounderline abstract_t">Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. JAMA Dermatol 2016; 152:52.</a></li><li><a class="nounderline abstract_t">Zarchi K, Dufour DN, Jemec GB. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol 2013; 149:1192.</a></li><li><a class="nounderline abstract_t">Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 2014; 70:243.</a></li><li><a class="nounderline abstract_t">van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology 2013; 226:97.</a></li><li><a class="nounderline abstract_t">Menis D, Maroñas-Jiménez L, Delgado-Marquez AM, et al. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol 2015; 172:810.</a></li><li><a class="nounderline abstract_t">Russo V, Alikhan A. Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa. J Drugs Dermatol 2016; 15:772.</a></li><li><a class="nounderline abstract_t">Glatt S, Jemec GBE, Forman S, et al. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. JAMA Dermatol 2021; 157:1279.</a></li><li><a class="nounderline abstract_t">Join-Lambert O, Coignard-Biehler H, Jais JP, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother 2016; 71:513.</a></li><li><a class="nounderline abstract_t">Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review. J Am Acad Dermatol 2019; 81:265.</a></li><li><a class="nounderline abstract_t">Houriet C, Seyed Jafari SM, Thomi R, et al. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases. JAMA Dermatol 2017; 153:1195.</a></li><li><a class="nounderline abstract_t">Anderson MD, Zauli S, Bettoli V, et al. Cyclosporine treatment of severe Hidradenitis suppurativa--A case series. J Dermatolog Treat 2016; 27:247.</a></li><li><a class="nounderline abstract_t">Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126:339.</a></li><li><a class="nounderline abstract_t">Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995; 88:289P.</a></li><li><a class="nounderline abstract_t">Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2006; 31:154.</a></li><li><a class="nounderline abstract_t">Ducroux E, Ocampo MA, Kanitakis J, et al. Hidradenitis suppurativa after renal transplantation: complete remission after switching from oral cyclosporine to oral tacrolimus. J Am Acad Dermatol 2014; 71:e210.</a></li><li><a class="nounderline abstract_t">Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. J Invest Dermatol 2018; 138:795.</a></li><li><a class="nounderline abstract_t">Gottlieb A, Natsis NE, Kerdel F, et al. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. J Invest Dermatol 2020; 140:1538.</a></li><li><a class="nounderline abstract_t">van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63:475.</a></li><li><a class="nounderline abstract_t">Brown SC, Kazzazi N, Lord PH. Surgical treatment of perineal hidradenitis suppurativa with special reference to recognition of the perianal form. Br J Surg 1986; 73:978.</a></li><li><a class="nounderline abstract_t">Dahmen RA, Gkalpakiotis S, Mardesicova L, et al. Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. J Dtsch Dermatol Ges 2019; 17:698.</a></li><li><a class="nounderline abstract_t">Mehdizadeh A, Hazen PG, Bechara FG, et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. J Am Acad Dermatol 2015; 73:S70.</a></li><li><a class="nounderline abstract_t">Lin CH, Chang KP, Huang SH. Deroofing: An Effective Method for Treating Chronic Diffuse Hidradenitis Suppurativa. Dermatol Surg 2016; 42:273.</a></li><li><a class="nounderline abstract_t">Vossen AR, van Straalen KR, Prens EP, van der Zee HH. Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study. J Am Acad Dermatol 2017; 76:155.</a></li><li><a class="nounderline abstract_t">Liy-Wong C, Pope E, Lara-Corrales I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol 2015; 73:S36.</a></li><li><a class="nounderline abstract_t">Mikkelsen PR, Jemec GB. Hidradenitis suppurativa in children and adolescents: a review of treatment options. Paediatr Drugs 2014; 16:483.</a></li><li><a class="nounderline abstract_t">Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 2009; 35:1188.</a></li><li><a class="nounderline abstract_t">Xu LY, Wright DR, Mahmoud BH, et al. Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment. Arch Dermatol 2011; 147:21.</a></li><li><a class="nounderline abstract_t">Highton L, Chan WY, Khwaja N, Laitung JK. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 2011; 128:459.</a></li><li><a class="nounderline abstract_t">Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 2011; 222:49.</a></li><li><a class="nounderline abstract_t">Delage M, Jais JP, Lam T, et al. Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients. J Am Acad Dermatol 2023; 88:94.</a></li><li><a class="nounderline abstract_t">Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol 2019; 80:80.</a></li><li><a class="nounderline abstract_t">Weber P, Seyed Jafari SM, Yawalkar N, Hunger RE. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. J Am Acad Dermatol 2017; 76:1189.</a></li><li><a class="nounderline abstract_t">Brocard A, Knol AC, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007; 214:325.</a></li><li><a class="nounderline abstract_t">Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012; 148:182.</a></li><li><a class="nounderline abstract_t">Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology 2009; 218:134.</a></li><li><a class="nounderline abstract_t">Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40:73.</a></li><li><a class="nounderline abstract_t">Verdolini R, Simonacci F, Menon S, et al. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol 2015; 150:155.</a></li><li><a class="nounderline abstract_t">Deckers IE, van der Zee HH, Balak DM, Prens EP. Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study. Br J Dermatol 2015; 172:828.</a></li><li><a class="nounderline abstract_t">Guillet A, Brocard A, Bach Ngohou K, et al. Verneuil's disease, innate immunity and vitamin D: a pilot study. J Eur Acad Dermatol Venereol 2015; 29:1347.</a></li><li><a class="nounderline abstract_t">Fröhlich D, Baaske D, Glatzel M. [Radiotherapy of hidradenitis suppurativa--still valid today?]. Strahlenther Onkol 2000; 176:286.</a></li><li><a class="nounderline abstract_t">Trombetta M, Werts ED, Parda D. The role of radiotherapy in the treatment of hidradenitis suppurativa: case report and review of the literature. Dermatol Online J 2010; 16:16.</a></li><li><a class="nounderline abstract_t">Gold M, Bridges TM, Bradshaw VL, Boring M. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004; 3:S32.</a></li><li><a class="nounderline abstract_t">Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol 2005; 152:803.</a></li><li><a class="nounderline abstract_t">Guglielmetti A, Bedoya J, Acuna M, et al. Successful aminolevulinic acid photodynamic therapy for recalcitrant severe hidradenitis suppurativa. Photodermatol Photoimmunol Photomed 2010; 26:110.</a></li><li><a class="nounderline abstract_t">Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. J Drugs Dermatol 2011; 10:381.</a></li><li><a class="nounderline abstract_t">Fadel MA, Tawfik AA. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol 2015; 40:116.</a></li><li><a class="nounderline abstract_t">Rodríguez-Prieto MÁ, Valladares-Narganes LM, González-Sixto B, Noguerol-Cal M. Efficacy of intralesional photodynamic therapy for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2013; 68:873.</a></li><li><a class="nounderline abstract_t">Agut-Busquet E, Romaní J, Gilaberte Y, et al. Photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: a retrospective follow-up study in 7 patients and a review of the literature. Photochem Photobiol Sci 2016; 15:1020.</a></li><li><a class="nounderline abstract_t">Feito-Rodríguez M, Sendagorta-Cudós E, Herranz-Pinto P, de Lucas-Laguna R. Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg 2009; 35:1300.</a></li><li><a class="nounderline abstract_t">O'Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg 2005; 116:1575.</a></li><li><a class="nounderline abstract_t">Pagliarello C, Fabrizi G, Feliciani C, Di Nuzzo S. Cryoinsufflation for Hurley stage II hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided. JAMA Dermatol 2014; 150:765.</a></li><li><a class="nounderline abstract_t">Tursi A. Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab. Dig Liver Dis 2016; 48:1511.</a></li><li><a class="nounderline abstract_t">Marques E, Arenberger P, Smetanová A, et al. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. Br J Dermatol 2021; 184:966.</a></li><li><a class="nounderline abstract_t">Licata G, Gambardella A, Buononato D, et al. A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. Int J Dermatol 2022; 61:e126.</a></li><li><a class="nounderline abstract_t">Savage KT, Santillan MR, Flood KS, et al. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep 2020; 6:99.</a></li><li><a class="nounderline abstract_t">Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol 2022; 186:803.</a></li><li><a class="nounderline abstract_t">Jennings L, Nestor L, Molloy O, et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol 2017; 177:858.</a></li><li><a class="nounderline abstract_t">Vossen ARJV, van Huijkelom MAPC, Nijsten TEC, et al. Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: Results of a randomized intrapatient-controlled trial. J Am Acad Dermatol 2019; 80:777.</a></li><li><a class="nounderline abstract_t">Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 1987; 294:487.</a></li><li><a class="nounderline abstract_t">Williams ST, Busby RC, DeMuth RJ, Nelson H. Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 1991; 26:456.</a></li><li><a class="nounderline abstract_t">Grewal NS, Wan DC, Roostaeian J, Rubayi SR. Marjolin ulcer in hidradenitis suppurativa: case reports. Ann Plast Surg 2010; 64:315.</a></li><li><a class="nounderline abstract_t">Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology 2010; 220:147.</a></li><li><a class="nounderline abstract_t">Makris GM, Poulakaki N, Papanota AM, et al. Vulvar, Perianal and Perineal Cancer After Hidradenitis Suppurativa: A Systematic Review and Pooled Analysis. Dermatol Surg 2017; 43:107.</a></li></ol></div><div id="topicVersionRevision">Topic 7605 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17097366" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Quality of life impairment in hidradenitis suppurativa: a study of 61 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30916383" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Even mild hidradenitis suppurativa impairs quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30627617" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526543" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Psychophysical aspects of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21394419" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Psychosocial impact of hidradenitis suppurativa: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22182915" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Profound disturbances of sexual health in patients with acne inversa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222447" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222447" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31705538" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8033378" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443481" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040429" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35207280" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28636793" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654696" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28219961" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30552762" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30872156" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26198191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnostic delay in hidradenitis suppurativa is a global problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31279015" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22339940" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Depression in patients with hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30872149" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509172" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of Long-term Opioid Use Among Opioid-Naive Patients With Hidradenitis Suppurativa in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26617352" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440440" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33493574" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31374127" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Identifying anaemia in a cohort of patients with hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796920" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recommendations for the management of comorbidity in hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236226" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical practice. Hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18674845" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406505" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393449" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cigarette smoking as a triggering factor of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885728" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577555" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The influence of body weight on the prevalence and severity of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082894" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hidradenitis suppurativa and smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21930119" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25640693" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843011" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2944534" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601419" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26080895" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A case series of 20 women with hidradenitis suppurativa treated with spironolactone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16019620" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hidradenitis suppurativa treated with finasteride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10722269" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Finasteride as a therapy for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730603" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30003993" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31602704" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Spironolactone therapy for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27386051" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Finasteride in Hidradenitis Suppurativa: A "Male" Therapy for a Predominantly "Female" Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882365" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Metformin for the treatment of hidradenitis suppurativa: a little help along the way.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30893570" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Metformin use in hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6347922" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Topical treatment of hidradenitis suppurativa with clindamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757878" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dapsone therapy for hidradenitis suppurativa: a series of 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971313" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hidradenitis suppurativa treated with dapsone: A case series of five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307940" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hypersensitivity reactions to dapsone: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692735" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19549239" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30502416" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281779" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19590173" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19590174" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634904" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27753139" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443004" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Interventions for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443004" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interventions for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27518661" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29860040" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36289787" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36461770" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36062429" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36294953" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24506875" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20874789" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996403" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Night blindness, vitamin A deficiency, and isotretinoin psychotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996403" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Night blindness, vitamin A deficiency, and isotretinoin psychotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36746171" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30674475" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24641123" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Four-weekly infliximab in the treatment of severe hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35790062" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20115947" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092698" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hidradenitis suppurativa: surgical and other management techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27340739" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Surgical Management of Hidradenitis Suppurativa: Outcomes of 590 Consecutive Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9810520" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Extent of surgery and recurrence rate of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027202" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Patient Satisfaction and Quality of Life Following Surgery for Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101775" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Management of recalcitrant hidradenitis suppurativa with ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605174" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641739" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579854" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966107" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Successful treatment of severe hidradenitis suppurativa with anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314876" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23713053" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25059730" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Two cases of severe hidradenitis suppurativa with failure of anakinra therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272089" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34406364" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565016" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30562567" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854317" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406923" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cyclosporine treatment of severe Hidradenitis suppurativa--A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178558" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636825" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cyclosporin-responsive hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16309527" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25437996" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hidradenitis suppurativa after renal transplantation: complete remission after switching from oral cyclosporine to oral tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29129600" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : MABp1 Targeting IL-1αfor Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004568" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20708472" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790962" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Surgical treatment of perineal hidradenitis suppurativa with special reference to recognition of the perianal form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31219670" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26470621" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808179" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Deroofing: An Effective Method for Treating Chronic Diffuse Hidradenitis Suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986138" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26470613" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Hidradenitis suppurativa in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234961" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Hidradenitis suppurativa in children and adolescents: a review of treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438670" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855672" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788837" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109728" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931082" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482392" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28522043" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460404" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22004878" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Hidradenitis suppurativa: the role of deficient cutaneous innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060466" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922015" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24927170" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25123023" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512084" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Verneuil's disease, innate immunity and vitamin D: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10897256" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : [Radiotherapy of hidradenitis suppurativa--still valid today?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178712" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : The role of radiotherapy in the treatment of hidradenitis suppurativa: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14964759" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : ALA-PDT and blue light therapy for hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840120" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415746" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Successful aminolevulinic acid photodynamic therapy for recalcitrant severe hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21455548" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262788" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602177" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Efficacy of intralesional photodynamic therapy for the treatment of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27417568" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: a retrospective follow-up study in 7 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19496796" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217533" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Treatment of hidradenitis suppurativa with botulinum toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24806911" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Cryoinsufflation for Hurley stage II hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27793616" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301601" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34151438" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31993474" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34978076" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27943236" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29940205" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: Results of a randomized intrapatient-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3103741" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Recurrence after surgical treatment of hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1952719" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Perineal hidradenitis suppurativa: presentation of two unusual complications and a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179481" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Marjolin ulcer in hidradenitis suppurativa: case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20029163" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27755170" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Vulvar, Perianal and Perineal Cancer After Hidradenitis Suppurativa: A Systematic Review and Pooled Analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
